What type of study is this?

This is a Case Report study (also classified as: Cohort Study, Systematic Review).

December 8, 2025BloodOpen Access

Caplacizumab for pediatric immune thrombotic thrombocytopenic purpura: A scoping review of current evidence

View Full Paper

Ask AI

Bookmark

Authors

Scoping review reports caplacizumab's efficacy and safety in pediatric iTTP patients, highlighting treatment variability and potential benefits.

Caplacizumab achieved rapid platelet recovery in pediatric patients, with 80% normalizing counts within four days.
Among 36 patients, 94% remained relapse-free, demonstrating effective management of immune thrombotic thrombocytopenic purpura.
Cohort studies and case series revealed a favorable safety profile, with infrequent mild adverse events reported among treated children.
Further pediatric-specific studies are needed to optimize dosing and monitor long-term outcomes in this population.

Al‐Mashdali et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Scoping review reports caplacizumab's efficacy and safety in pediatric iTTP patients, highlighting treatment variability and potential benefits.